Neuroretinitis after the second injection of a SARS-CoV-2-vaccine: A case report

Lee, Chaeyeon; Park, Kyung-Ah; Ham, Don-Il; Seong, Minjung; Kim, Hyung-Jin; Lee, Ga-In; Oh, Sei Yeul

doi:10.1016/j.ajoc.2022.101592

Cited by 11 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since their deployment, COVID-19 vaccines have been linked to various ophthalmic manifestations [ 11 , 12 ]. These manifestations have involved the orbit [ 13 ], cornea [ 14 , 15 ], uvea [ 16 , 17 ], optic nerve [ 18 , 19 ], retina [ 20 , 21 ], and retinal vessels [ 22 ]. Regarding neuro-ophthalmic manifestations, several cranial nerve palsies were reported following COVID-19 vaccines that involved the oculomotor [ 23 ], abducens [ 24 ], and facial nerves [ 25 , 26 , 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients

Elnahry

Al-Nawaflh²,

Eldin³

et al. 2022

Vaccines

View full text Add to dashboard Cite

We provide a systematic review of published cases of optic neuropathy following COVID-19 vaccination. We used Ovid MEDLINE, PubMed, and Google Scholar. Search terms included: “COVID-19 vaccination”, “optic neuropathy”, “optic neuritis”, and “ischemic optic neuropathy”. The titles and abstracts were screened, then the full texts were reviewed. Sixty eyes from forty-five patients (28 females) were included. Eighteen eyes from fourteen patients (31.1%) were diagnosed with anterior ischemic optic neuropathy (AION), while 34 eyes from 26 patients (57.8%) were diagnosed with optic neuritis (ON). Other conditions included autoimmune optic neuropathy and Leber hereditary optic neuropathy. Fifteen patients (33.3%) had bilateral involvement. The mean age of all patients was 47.4 ± 17.1 years. The mean age of AION patients was 62.9 ± 12.2 years and of ON patients was 39.7 ± 12.8 years (p < 0.001). The mean time from vaccination to ophthalmic symptoms was 9.6 ± 8.7 days. The mean presenting visual acuity (VA) was logMAR 0.990 ± 0.924. For 41 eyes with available follow-up, the mean presenting VA was logMAR 0.842 ± 0.885, which improved to logMAR 0.523 ± 0.860 at final follow-up (p < 0.001). COVID-19 vaccination may be associated with different forms of optic neuropathy. Patients diagnosed with ON were more likely to be younger and to experience visual improvement. More studies are needed to further characterize optic neuropathies associated with COVID-19 vaccination.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients

Elnahry

Al-Nawaflh²,

Eldin³

et al. 2022

Vaccines

View full text Add to dashboard Cite

show abstract

“…The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow chart is shown in figure 1. There were 34 studies of ON following COVID-19 infection,12–45 and an equal number of publications reported patients with ON post-COVID-19 vaccination 46–78. There were 19 case series and the remaining 49 were case reports.…”

Section: Resultsmentioning

confidence: 99%

Systematic review exploring the clinical features of optic neuritis after SARS-CoV infection and vaccination

Georganta,

Chasapi,

Smith

et al. 2023

BMJ Open Ophth

View full text Add to dashboard Cite

BackgroundThis study aims to characterise the symptoms and clinical features of optic neuritis (ON) following SARS-CoV-2 infection and vaccination.MethodA literature search was conducted in four databases (PubMed, Medline, Embase and Google Scholar) to identify relevant case reports and case series. The records were screened and articles adhering to the inclusion criteria were critically appraised.ResultsSixty-eight studies were found to be eligible for inclusion, including 34 reporting ON following SARS-CoV-2 infection and an equal number reporting cases postvaccination. In total 93 patients and 125 eyes were included. The infection cohort included 42 patients and 56 eyes, 51.2% were female and 33.3% experienced bilateral ON. The mean visual acuity was 1.64 log of minimum angle of resolution (LogMAR), while pain was present in 77.8%. Oligoclonal bands were present in 3 patients, myelin oligodendrocyte glycoprotein (MOG) antibodies in 18 patients and AQP-4 antibodies in 4 patients. The vaccination cohort included 51 patients and 69 eyes. 60.8% were female and 35.3% had a bilateral ON. The mean visual acuity was 0.93 LogMAR. Oligoclonal bands were present in 46.7%, MOG antibodies in nine patients and AQP-4 antibodies in three patients.ConclusionPatients with ON post-SARS-CoV infection were more likely to experience severe visual impairment than in cases following vaccination. Further research is required to outline the clinical features of ON after COVID-19 infection and vaccination, and establish causality.

show abstract

“…A total of 65 studies were both qualitatively and quantitatively analyzed ( Table 1 ) [ 1 , 5 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ,…”

Section: Resultsmentioning

confidence: 99%

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

et al. 2022

View full text Add to dashboard Cite

Numerous complications following COVID-19 vaccination has been reported in the literature, with an increasing body of evidence reporting vaccination-associated uveitis (VAU). In this systematic review, we searched six electronic databases for articles reporting the occurrence of VAU following COVID-19 vaccination. Data were synthesized with emphasis on patients’ characteristics [age, gender], vaccination characteristics [type, dose], and outcome findings [type, nature, laterality, course, location, onset, underlying cause, and associated findings]. Data are presented as numbers (percentages) for categorical data and as mean (standard deviation) for continuous data. Sixty-five studies were finally included [43 case reports, 16 case series, four cohort, one cross-sectional, and one registry-based study]. VAU occurred in 1526 cases, most commonly in females (68.93%) and middle-aged individuals (41–50 years: 19.71%), following the first dose (49.35%) of vaccination, especially in those who received Pfizer (77.90%). VAU occurred acutely (71.77%) as an inflammatory reaction (88.29%) in unilateral eyes (77.69%), particularly in the anterior portion of the uvea (54.13%). Importantly, most cases had a new onset (69.92%) while only a limited portion of cases had a reactivation of previous uveitis condition. In conclusion, although rare, uveitis following COVID-19 vaccination should be considered in new-onset and recurrent cases presenting with either acute or chronic events.

show abstract

Neuroretinitis after the second injection of a SARS-CoV-2-vaccine: A case report

Cited by 11 publications

References 26 publications

COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients

COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients

Systematic review exploring the clinical features of optic neuritis after SARS-CoV infection and vaccination

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

Contact Info

Product

Resources

About